Loading
OPB-101 is an experimental autologous CAR T-cell therapy from Outpace Bio, in phase 1 trials for platinum-resistant ovarian cancer; its current status is not stated.
OPB-101 is an autologous CAR T-cell therapy from Outpace Bio. Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen. Its furthest stage is phase 1, for platinum-resistant ovarian cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07030907 terminated, reason "Business decision"; OPB-101 is no longer on the company pipeline page (checked 3 Nov 2026). No source states it is discontinued. Whether it works in people has not been established unless a trial below reports it.
Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen. Connects to Mesothelin.
1.OPB-101 slips into a pocket on Mesothelin.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OPB-101" OR ABSTRACT:"OPB-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OPB-101, not a curated reading list.
Shares Outpace Bio, Platinum-resistant ovarian cancer and the tag pipeline.
Shares Outpace Bio, Platinum-resistant ovarian cancer and the tag pipeline.
Shares Outpace Bio and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/